IMT1（Cat No.:I045295）is a small-molecule inhibitor designed to target specific protein–protein interactions involved in tumor growth and immune regulation. By selectively binding to its intended molecular target, IMT1 disrupts oncogenic signaling pathways, leading to reduced cancer cell proliferation and enhanced apoptosis. Preclinical studies indicate potential applications in immuno-oncology, where IMT1 may also modulate immune cell activation to improve antitumor responses. Its favorable pharmacokinetic profile and selectivity make it a promising lead compound for further development, serving as both a research tool and a potential therapeutic candidate in precision cancer treatment strategies.